Search
forLearn
5 / 801 resultslearn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
learn biovolume 128
learn biotinyl
learn vitamin-b7
Research
5 / 1000+ results
research PSS33 REAL-LIFE DOSING OF BIOLOGICS IN PLAQUE PSORIASIS—A GERMAN SURVEY
Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.
research PSS37 CATARACT SURGERY GUIDELINES IN EUROPE: A LITERATURE REVIEW AND DOCUMENT SEARCH IN 15 COUNTRIES
Cataract surgery guidelines vary across Europe, and generic finasteride sales for hair loss have grown due to pill splitting.
research PSS36 ECONOMIC ANALYSIS OF CATARACT SURGERY IN EUROPE:AN ANALYSIS OF HOSPITAL DATABASES AVAILABLE IN 11 COUNTRIES
Cataract surgery in Europe varies in frequency and cost between countries.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research PSS34 THE IMPACT OF POTENTIAL PILL SPLITTING ON GENERIC AND BRANDED FINASTERIDE UPTAKE
Pill splitting increased generic finasteride sales but didn't affect branded finasteride sales.
Community Join
5 / 1000+ resultscommunity GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.